In the following video, Motley Fool health care bureau chief Brenton Flynn discusses the lack of a pathway in the United States for approving drugs that are being called "biosimilars," in that they are similar to biological large-molecule drugs like how generic pharmaceuticals currently are similar to small-molecule drugs. Brenton discusses why this has remained such an untapped market in the U.S. and what the difficulties are in producing these far more complex drugs in the form of a marketable generic. He also tells us which companies stand to benefit from legislation putting a pathway to approval for these drugs into place in the U.S., and why companies like AbbVie (ABBV 2.35%) would benefit from such legislation being delayed.